Indeed, we found that the clones that highly expressed E-cadherin (Du145-EL and PC3/M-EL) contained many more CD44+/CD24- prostate cancer TICs [28, 29] than the E-cadherin-low clones (Du145-ML and PC3/M-ML) (Figures 1F and Supplementary Figure 1D). This evidence concerns the gene CD44 and prostate carcinoma.